Using Analytics to Maximize Copay Program Effectiveness

Click here to view the session

As manufacturers began to shift from pure product sampling strategies to more blended ones comprised of sampling, vouchers, and copays, the advantages generated were clearly evident: the entire cost of the product was no longer always being subsidized. As such, manufacturers were content to receive data on the numbers of redemptions, patients, and prescribers participating. However, as the copay industry has matured, these measures have become less and less adequate. Instead, pharmaceutical manufacturers are looking to analytics, with their rich sources of evidence, demonstrations of convincing payback, and sophisticated predictive models as requirements of their patient access suppliers. In this webcast, TrialCard provides an overview of the analytic data that we use to help our manufacturers to design the most effective campaigns and to assess their effectiveness.


Featured Speaker:
Paul LeVine, Vice President of Analytic Services, TrialCard


Sponsored by:

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


As US pharma continued its quest for a Grand Prix at the Lions Health international festival of creativity, MM&M went on location to Cannes, France. Missed our coverage from June? Now, we're giving you an opportunity to catch up on some of what you missed. Download our e-book on the two-day festival, recapping the event, rounding up the best of the speakers, offering perspective and listing all of the winners. Click here to download.


The most recent MM&M Skill Sets Live event surveyed a range of issues relating to one of the hottest promotional spaces in healthcare. Speakers and panelists at the morning-long session, including promotional- and multichannel-minded executives from GSK, Epocrates, Treato and Montefiore Medical Center, weighed in on topics designed to help marketers demystify the challenges associated with non-personal promotion. Click here.